ClinConnect ClinConnect Logo
Search / Trial NCT04310059

Effect of Folic Acid Supplementation in Pregnant Women Having Thalassaemia Trait

Launched by THE UNIVERSITY OF HONG KONG · Mar 12, 2020

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how folic acid supplementation affects pregnant women who have thalassaemia trait, a condition that can impact the production of red blood cells. Folic acid is important for preventing certain birth defects, especially during the early weeks of pregnancy. The goal is to find out the best dosage of folic acid for women with thalassaemia, as they may have a higher risk of not having enough folate, which is crucial for their health and their baby's health.

To participate in this study, women need to be pregnant with a single baby and have either alpha or beta thalassaemia trait. However, there are some criteria that would exclude them, such as if they are taking high doses of folic acid before or during pregnancy, or if they have certain other health conditions. Participants will be monitored throughout their pregnancy to see how the folic acid affects their health and the health of their baby. It's important to know that this trial is not yet recruiting participants, but it aims to fill knowledge gaps about folic acid and thalassaemia in pregnancy.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Singleton pregnancy
  • Alpha thalassaemia trait
  • Beta thalassaemia trait
  • Exclusion Criteria:
  • Women taking over 0.6mg folic acid daily for 3 months or more prior to and during pregnancy
  • Gestational age \> 16 weeks at first antenatal visit
  • Women age =\< 18 years old
  • Booking BMI =\< 18 or \>= 35
  • Serum ferritin level \< 30ug/L or 68 pmol/L
  • Concomitant alpha and beta thalassaemia
  • Hb H disease
  • Beta thalassaemia major
  • Beta thalassaemia intermediate
  • Thalassaemia other than alpha or beta type
  • Women on long term medications
  • Women with risk factors for NTD
  • Women with known epilepsy
  • Women with bariatric surgery or malabsorption diseases
  • Women with known MTHFR polymorphism
  • Vegetarian

About The University Of Hong Kong

The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials